ArticleAnnals of hematology2026
Factors contributing to the development of hemophilic arthropathy: A real-world study.
Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hemophilia A is a rare X-linked bleeding disorder that often leads to hemophilic arthropathy (HA), a major cause of disability and an important healthcare burden worldwide. To identify the factors associated with HA among Colombian patients with severe hemophilia A and to evaluate how current clinical practice aligns with international care recommendations. This study employed a convergent mixed-methods design combining a targeted literature review (TLR), an analysis of 90 anonymized physician-collected patient diaries (PDs), and semistructured interviews with hematologists. Associations were assessed using odds ratios (ORs) and mean differences. The findings were triangulated to inform expert prioritization of risk and protective factors. PDs were mainly obtained from adults (38.9%) and children (3–11 years) (31.1%). Key gaps in clinical practice included the limited use of genetic testing (31.1%) and laboratory monitoring (< 20%). Physical activity (OR: 0.16; 95% CI: 0.06–0.47) and primary prophylaxis (OR: 0.07 vs. secondary; OR: 0.10 vs. on-demand) were considered protective factors for joint damage. HA bleeding episodes during the prior 12 months (OR: 4.6; 95% CI: 1.8–11.8) and primary prophylaxis (OR: 0.2 vs. secondary prophylaxis; OR: 0.3 vs. tertiary prophylaxis) were associated with HA. Patients with joint damage/HA had a relative delay in prophylaxis initiation compared with those without the conditions (median, 155/191 vs. 50/60.5 months, respectively). In this study, early prophylaxis and physical activity were revealed as protective factors for HA. Gaps remain in local care, underscoring the need to adopt guidelines and personalized treatment to improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.